Latest News

 Filter by Provider

Stephanie Link, chief investment strategist at Hightower Advisors, chooses Truist Financial (TFC) as her final trade, supported by Morgan Stanley's upgrade. Rob Sechan picks Netflix (NFLX), Joshua Brown recommends Joby Aviation (JOBY), and Malcolm Ethridge selects Zscaler (ZS) ahead of quarterly earnings.

CD rates are still elevated in 2026. Here's the simplest strategy to lock in yield without getting stuck if rates fall.

Alphabet's Google (NASDAQ: GOOGL) (NASDAQ: GOOG) and OpenAI employees are raising their voices against the company's plans to collaborate with the Pentagon on artificial intelligence technology.

Bitwise Chief Investment Officer Matt Hougan dismissed conspiracy theories blaming Jane Street and others for Bitcoin’s (CRYPTO: BTC

This company is helping resolve a key strategic rare earth supply chain problem for the U.S.

KORE stated that Searchlight and Abry will acquire all shares of the company’s issued and outstanding common stock that they currently don’t own in an all-cash transaction valued at nearly $726 million.

Neurogene stock jumps after FDA grants Breakthrough Therapy status to NGN-401 for Rett syndrome treatment.

Shares of Micron are up more than 250% since the summer.

While Chipotle Mexican Grill has underperformed relative to its sector over the past year, Wall Street analysts maintain a moderately optimistic outlook on the stock’s prospects.

Check out the companies making headlines this week:

The company priced a $48 million registered direct offering to a single institutional investor.

Microsoft and Meta Platforms are trading at attractive levels.

Welltower is a much healthier REIT.

Salesforce Inc. (NYSE: CRM) shares edged lower in Friday's premarket trading, despite a standout quarterly performance.

Here's what the benchmarks look like for ideal retirement savings at age 50 -- and what to do if you're behind.

Sherwin-Williams has underperformed other basic materials stocks over the past year, yet analysts remain moderately optimistic about the stock’s future outlook.

The company said that the U.S. Food and Drug Administration granted a key designation for its investigational gene therapy targeting Rett syndrome.

If you're going to make a change, do so carefully.

Cadence Design has outperformed the Dow over the past year, and analysts remain highly bullish on its future outlook.